Deborah Karlak Email

Controller . VenatoRx Pharmaceuticals

Current Roles

Employees:
77
Revenue:
$15.5M
About
Led by a world-class team of pharmaceutical veterans, VenatoRx is a private pharmaceutical company that is developing a new wave of anti-infective products to address increasing medical needs. VenatoRx's lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. Early clinical studies of cefepime/VNRX-5133 have been completed and VenatoRx plans to start Phase 3 pivotal trials in the second half of 2018. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.
VenatoRx Pharmaceuticals Address
74 E. Swedesford Road
Malvern, PA
United States
VenatoRx Pharmaceuticals Email

Past Companies

Venatorx Pharmaceuticals, Inc.Controller
AccessIT GroupVice President Of Finance and Administration
Helius Medical TechnologiesDirector Of Finance And Accounting

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.